TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lifecore Biomedical ( (LFCR) ) has provided an announcement.
On September 22, 2025, Lifecore Biomedical‘s Compensation Committee approved a new cash incentive pay plan for the period from May 26, 2025, to December 31, 2025, due to a fiscal year change. This plan replaces the previously approved 2026 Bonus Plan and is designed to align executive bonuses with company financial performance goals, such as Adjusted EBITDA and total revenue, with a maximum bonus cap of 200% of the target level.
The most recent analyst rating on (LFCR) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Lifecore Biomedical stock, see the LFCR Stock Forecast page.
Spark’s Take on LFCR Stock
According to Spark, TipRanks’ AI Analyst, LFCR is a Neutral.
Lifecore Biomedical’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue, high leverage, and negative cash flows. Technical analysis provides some neutral signals, but valuation remains poor due to negative earnings and lack of dividends.
To see Spark’s full report on LFCR stock, click here.
More about Lifecore Biomedical
Lifecore Biomedical, Inc. operates in the biomedical industry, focusing on developing and providing specialized products and services. The company is known for its expertise in hyaluronic acid-based products and solutions, catering to various healthcare and medical applications.
Average Trading Volume: 158,292
Technical Sentiment Signal: Sell
Current Market Cap: $264.3M
For a thorough assessment of LFCR stock, go to TipRanks’ Stock Analysis page.